Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lymphoid leukemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    380 result(s) found for: Lymphoid leukemia. Displaying page 9 of 19.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2018-003006-32 Sponsor Protocol Number: ALL2418 Start Date*: 2019-07-08
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: "A Phase IIA Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin (IO) in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with positive Minimal Residual Disease before any Hemato...
    Medical condition: Acute B-cell Lymphoblastic Leukemia with minimal residual positive disease prior to haematopoietic stem cell transplantation in adult patients
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000159-14 Sponsor Protocol Number: CLL1818 Start Date*: 2019-09-17
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: Prospective study on the incidence of hepatitis B virus reactivation in untreated patients with diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive treated with Rituximab, Chemot...
    Medical condition: Chronic lymphocytic leukemia is a neoplasm of the lymphatic system characterized by an accumulation of B lymphocytes in peripheral blood, bone marrow and lymphatic organs. Diffuse Large Cell B Lymp...
    Disease: Version SOC Term Classification Code Term Level
    22.1 10021881 - Infections and infestations 10058827 Hepatitis B reactivation PT
    20.0 10021881 - Infections and infestations 10019731 Hepatitis B PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003314-41 Sponsor Protocol Number: GS-US-312-0133 Start Date*: 2014-08-05
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia with 17p Deletion
    Medical condition: Chronic Lymphocytic Leukemia with 17p deletion
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10068919 B-cell chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) GB (Prematurely Ended) PT (Prematurely Ended) HU (Completed) IT (Completed) BE (Prematurely Ended) CZ (Prematurely Ended) DK (Prematurely Ended) ES (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012717-22 Sponsor Protocol Number: UCL/08/0167 Start Date*: 2010-01-13
    Sponsor Name:University College London
    Full Title: UKALL14 - A randomized trial for adults with newly diagnosed acute lymphoblastic leukemia
    Medical condition: Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2004-001647-30 Sponsor Protocol Number: ESPHALL Start Date*: 2004-04-28
    Sponsor Name:A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA
    Full Title: An open-label study to evaluate the safety and efficacy of IMATINIB with chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL)
    Medical condition: Children and adolescents aged 1-17 years at diagnosis, with Ph+ALL
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016075-30 Sponsor Protocol Number: GIMEMA LAL1308 Start Date*: 2010-07-09
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL`ADULTO
    Full Title: Therapy of the Young Adult Acute Lymphoblastic Leukemia (ALL): treatment intensification of the pediatric protocol AIEOP LLA-2000
    Medical condition: Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000844 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003517-17 Sponsor Protocol Number: ALL2518 Start Date*: 2019-09-26
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: Asparaginase Activity Monitoring (AAM) in adult patients with Acute Lymphoblastic Leukemia (ALL).
    Medical condition: Adult patients, aged between 18 and 65, diagnosed with Acute Ph Lymphoblastic Leukemia negative (LAL Ph-) untreated, with a favorable impact on the prognosis.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10060390 Leukaemia lymphoblastic acute LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-004251-23 Sponsor Protocol Number: LAL2317 Start Date*: 2018-04-26
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: National Treatment Program with Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease Response and Survival in Philadelphia Chromosome-Negative B-Cell
    Medical condition: Acute Lymphoblastic Leukemia Philadelphia Chromosome Negative (Ph-)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003667-11 Sponsor Protocol Number: M15-550 Start Date*: 2016-08-01
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: Open-Label, Single Arm, Phase 3B, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT 199) in Relapsed/Refractory Subjects with Chronic Lymphocytic Leukemia (CLL) (VENICE I)
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) SE (Completed) BE (Completed) NL (Completed) DE (Completed) AT (Completed) IE (Completed) PT (Completed) FI (Completed) DK (Completed) ES (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015118-23 Sponsor Protocol Number: DASA-TRAS Start Date*: 2010-01-05
    Sponsor Name:GETH
    Full Title: ESTUDIO PILOTO FASE II MULTICÉNTRICO, NO ALEATORIZADO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE DASATINIB TRAS TRASPLANTE ALOGÉNICO DE PROGENITORES HEMOPOYÉTICOS EN PACIENTES CON LEUCEMIA AGUDA LINFO...
    Medical condition: Evaluar la eficacia del mantenimiento con dasatinib en términos de Supervivencia Libre de Enfermedad a 2 años, estimado según curvas de Kaplan-Meier, en pacientes con Leucemia Linfoblástica Aguda P...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10024338 Leukemia lymphoblastic acute LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002761-35 Sponsor Protocol Number: LAL1811 Start Date*: 2012-11-14
    Sponsor Name:INCYTE Biosciences International Sarl
    Full Title: Trattamento di prima linea della Leucemia Linfoblastica Acuta (LLA) Philadelphia positiva (Ph+)/BCR/ABL+ con un nuovo potente inibitore delle Tirosin-chinasi (TKI), AP24534 (Ponatinib). Studio mult...
    Medical condition: Ph positive (Ph+)/Bcr-Abl positive Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012518-39 Sponsor Protocol Number: OMB112517 Start Date*: 2009-12-28
    Sponsor Name:GlaxoSmithKline Research and Development
    Full Title: A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia (CLL) who have responde...
    Medical condition: Subjects who are in CR or PR after 1 or 2 treatments for relapsed CLL
    Disease: Version SOC Term Classification Code Term Level
    12.1 10008959 Chronic lymphocytic leukaemia (in remission) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) SE (Completed) FI (Prematurely Ended) ES (Completed) FR (Prematurely Ended) DK (Completed) HU (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2007-005487-28 Sponsor Protocol Number: HOVON88CLL Start Date*: 2008-09-17
    Sponsor Name:HOVON Foundation
    Full Title: Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning for High-risk Relapsed or Refractory CLL
    Medical condition: Chronic lymphocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10008978 Chronic lymphocytic leukemia refractory LLT
    14.1 100000004864 10008977 Chronic lymphocytic leukemia recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001937-16 Sponsor Protocol Number: AUTO1-AL1 Start Date*: 2020-02-17
    Sponsor Name:Autolus Limited
    Full Title: An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating The Safety and Efficacy Of AUTO1, A CAR T Cell Treatment Targeting CD19, In Adult Patients With Relapsed Or Refractory B Cell Acute Lymphob...
    Medical condition: Relapsed or refractory B cell acute lymphoblastic leukaemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-004800-23 Sponsor Protocol Number: RG-17-241 Start Date*: 2018-06-12
    Sponsor Name:University of Birmingham
    Full Title: A comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in co...
    Medical condition: Acute Lymphoblastic Leukaemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-001810-24 Sponsor Protocol Number: BO25323 Start Date*: 2014-12-17
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PROSPECTIVE, OPEN-LABEL, MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX (GDC-0199/ABT 199) VERSUS OBINUTUZUMAB AND ...
    Medical condition: chronic lymphocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) DK (Trial now transitioned) GB (GB - no longer in EU/EEA) EE (Trial now transitioned) AT (Trial now transitioned) BG (Trial now transitioned) ES (Ongoing) HR (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2016-004672-21 Sponsor Protocol Number: CR-AIR-009 Start Date*: 2017-06-15
    Sponsor Name:Kiadis Pharma Netherlands B.V.
    Full Title: A Phase III, multicenter, randomized controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101, a T-lymphocyte enriched leukocyte preparation de...
    Medical condition: Patients with a hematologic malignancy (AML, ALL, or MDS) who are eligible for a haploidentical HSCT
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000845 Acute lymphoblastic leukemia LLT
    20.0 10042613 - Surgical and medical procedures 10059044 Allogeneic peripheral hematopoietic stem cell transplant LLT
    20.0 10042613 - Surgical and medical procedures 10027703 Mismatched donor bone marrow transplantation therapy PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) ES (Completed) PT (Completed) NL (Prematurely Ended) HR (Completed) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012718-35 Sponsor Protocol Number: Loulla001 Start Date*: 2010-05-05
    Sponsor Name:Only For Children Pharmaceuticals
    Full Title: An open-label, randomised crossover pharmacokinetic, palatability and safety study to assess the bioavailability of a new 6MP oral liquid formulation by comparison to a currently registered 6MP 50 ...
    Medical condition: Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Ongoing) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003639-31 Sponsor Protocol Number: IPI-145-12 Start Date*: 2014-11-06
    Sponsor Name:Infinity Pharmaceuticals, Inc
    Full Title: A Study of IPI-145 and Ofatumumab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07
    Medical condition: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) HU (Completed) ES (Completed) GB (Completed) BE (Completed) AT (Completed) DE (Completed) FR (Completed) LV (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004699-77 Sponsor Protocol Number: 54179060CLL3011 Start Date*: 2018-06-04
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Open-label, Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First-line Treatment of Subjects with Chronic Lymphocytic Leuke...
    Medical condition: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 00:49:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA